BCRX stock forecast
Our latest prediction for BioCryst Pharmaceuticals, Inc.'s stock price was made on the Aug. 11, 2020 when the stock price was at 3.96$.
In the short term (2weeks), BCRX's stock price should underperform the market by -0.19%. During that period the price should oscillate between -10.74% and +13.37%.
In the medium term (3months), BCRX's stock price should underperform the market by -8.17%. During that period the price should oscillate between -44.21% and +33.52%.Get email alerts
Create a solid portfolio with BCRX
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
At the moment the company generates 49M USD in revenues.
On its last earning announcement, the company reported a loss of -0.80$ per share.
The book value per share is 0.42$
Three months stock forecastAug. 11, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|